G
Geoffrey C. Gurtner
Researcher at Stanford University
Publications - 478
Citations - 32002
Geoffrey C. Gurtner is an academic researcher from Stanford University. The author has contributed to research in topics: Wound healing & Medicine. The author has an hindex of 76, co-authored 423 publications receiving 25985 citations. Previous affiliations of Geoffrey C. Gurtner include Duke University & York University.
Papers
More filters
Journal ArticleDOI
Abstract 29: Endothelial CXCL12 Recruits a Novel Circulating Progenitor Cell in Response to Tissue Injury
Zeshaan N. Maan,Dominik Duscher,Alexander J. Whittam,Ivan N. Vial,Michael Januszyk,Lauren H. Fischer,Robert C. Rennert,Melanie Rodrigues,Michael S. Hu,Graham G. Walmsley,Michael T. Longaker,Geoffrey C. Gurtner +11 more
TL;DR: H development was monitored by weekly ultrasound (US) Doppler, which detected blood flow within abnormal dilated vasculature, while normal capillary flow was beyond its sensitivity.
Journal ArticleDOI
Correction to: Two-Stage Versus One-Stage Nipple-Sparing Mastectomy: Timing of Surgery Prevents Nipple Loss.
Journal ArticleDOI
Understanding regulatory pathways of neovascularization in diabetes
Zeshaan N. Maan,Melanie Rodrigues,Robert C. Rennert,Arnetha J. Whitmore,Dominik Duscher,Michael Januszyk,Michael S. Hu,Alexander J. Whittam,Christopher R. Davis,Geoffrey C. Gurtner +9 more
TL;DR: The mechanisms by which hyperglycemia disrupts chemokine expression and function, including the critical hypoxia inducible factor-1 axis are explored, with particular emphasis on the therapeutic potential of strategies addressing these pathways.
Journal ArticleDOI
Profibrotic Signaling Pathways and Surface Markers Are Up-Regulated in Fibroblasts of Human Striae Distensae and in a Mouse Model System
Mimi R. Borrelli,Michelle Griffin,Kellen Chen,Nestor M. Deleon Diaz,Sandeep Adem,Shamik Mascharak,Abra H. Shen,Ledibabari M. Ngaage,Nicolette Lewis,Michael T. Longaker,Geoffrey C. Gurtner,Derrick C. Wan,H. P. Lorenz +12 more
TL;DR: The authors’ mouse model of striae distensae can be used as a platform to test the efficacy of potential therapeutic agents and CD26 and CD74 are promising surface markers that may be targeted therapeutically.